D. Boral Capital Reaffirms Buy Rating for Plus Therapeutics (NASDAQ:PSTV)

Plus Therapeutics (NASDAQ:PSTV)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $5.00 target price on the stock.

A number of other brokerages also recently commented on PSTV. D Boral Capital upgraded shares of Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 3rd. Zacks Research upgraded shares of Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th. Maxim Group dropped their target price on shares of Plus Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Monday, August 18th. HC Wainwright dropped their target price on shares of Plus Therapeutics from $5.50 to $3.00 and set a “buy” rating on the stock in a research note on Friday, June 27th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $8.00.

Plus Therapeutics Trading Down 4.8%

Shares of NASDAQ:PSTV opened at $0.59 on Tuesday. The company has a market capitalization of $58.51 million, a price-to-earnings ratio of -0.26 and a beta of 0.81. Plus Therapeutics has a 12 month low of $0.16 and a 12 month high of $2.31. The firm’s 50-day moving average is $0.56 and its 200 day moving average is $0.52.

Plus Therapeutics (NASDAQ:PSTV) last issued its earnings results on Thursday, August 14th. The company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.08. The company had revenue of $1.39 million during the quarter, compared to the consensus estimate of $1.08 million. As a group, equities analysts forecast that Plus Therapeutics will post -2.3 EPS for the current fiscal year.

Insider Activity

In other Plus Therapeutics news, Director Robert P. Lenk acquired 110,000 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were purchased at an average cost of $0.49 per share, for a total transaction of $53,900.00. Following the completion of the purchase, the director owned 139,327 shares in the company, valued at approximately $68,270.23. This trade represents a 375.08% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.79% of the company’s stock.

Hedge Funds Weigh In On Plus Therapeutics

A hedge fund recently bought a new stake in Plus Therapeutics stock. Jane Street Group LLC acquired a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 117,454 shares of the company’s stock, valued at approximately $41,000. Jane Street Group LLC owned approximately 0.19% of Plus Therapeutics as of its most recent filing with the Securities & Exchange Commission. 3.28% of the stock is currently owned by institutional investors.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.